Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil Vaccine with Chemotherapy in Recurrent Ovarian Cancer
NCT01867086Phase 2Completed
- Sponsor
- Gradalis, Inc.
- Start
- Jun 2013
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemogenovatucel-T in ovarian cancer, sponsored by Gradalis, Inc. Primary endpoints: Time to Progression at 24 months and Response Rate at 12 months. Started Jun 2013; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01867086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867086.